Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Issue 5 (10th May 2018)

• Record Type: Journal Article
• Authors: Humbert, Marc; Taillé, Camille; Mala, Laurence; Le Gros, Vincent; Just, Jocelyne; Molimard, Mathieu
• Other Names: author non-byline.; Agossou M. author non-byline.; Appere de Vecchi C. author non-byline.; Barbare E. author non-byline.; Barbry M. author non-byline.; Belleguic-Lebreton C. author non-byline.; Benhamou D. author non-byline.; Bentaleb A. author non-byline.; Blanc A. author non-byline.; Bonniaud P. author non-byline.; Bourgoin M. author non-byline.; Brouard J. author non-byline.; Broussier P-M. author non-byline.; Caimmi D. author non-byline.; Catherinot E. author non-byline.; Chiron R. author non-byline.; Claussner-Paulignan M. author non-byline.; Combe-Cayla P. author non-byline.; Cros P. author non-byline.; Dauriat G. author non-byline.; Delaisi B. author non-byline.; Devouassoux G. author non-byline.; Didi T. author non-byline.; Didier A. author non-byline.; Dominique S. author non-byline.; Dumont P. author non-byline.; Dury S. author non-byline.; Dusser D. author non-byline.; Fayon M. author non-byline.; Gainet-Brun M. author non-byline.; Garcia G. author non-byline.; Guilleminault L. author non-byline.; Hesse N. author non-byline.; Jeandeau S. author non-byline.; Jubin V. author non-byline.; Just J. author non-byline.; Just N. author non-byline.; Kelkel P-E. author non-byline.; Kerjan A-S. author non-byline.; Labbe A. author non-byline.; Laize H. author non-byline.; Laoudi Y. author non-byline.; Larrousse M. author non-byline.; Le Guen Y. author non-byline.; Leleu O. author non-byline.; Letanche G. author non-byline.; Lorillon G. author non-byline.; Mangiapan G. author non-byline.; Marangoni E. author non-byline.; Marchand-Adam S. author non-byline.; Martin P. author non-byline.; Maurer C. author non-byline.; Menivale F. author non-byline.; Mouget B. author non-byline.; Muller D. author non-byline.; Nasr M. author non-byline.; Nguyen L. author non-byline.; Oster J-P. author non-byline.; Pegliasco H. author non-byline.; Philippe B. author non-byline.; Pin I. author non-byline.; Pison C. author non-byline.; Proust A. author non-byline.; Prudhomme A. author non-byline.; Radu C. author non-byline.; Rakoto A. author non-byline.; Rochefort-Morel C. author non-byline.; Rolland-Debord C. author non-byline.; Romand P. author non-byline.; Roux P. author non-byline.; Sattler C. author non-byline.; Siret D. author non-byline.; Taillé C. author non-byline.; Tetu L. author non-byline.; Tiotiu A-I. author non-byline.; Tummino C. author non-byline.; Valcke J. author non-byline.; Verdier S. author non-byline.; Vigneron P. author non-byline.; Virally J. author non-byline.; Wanin S. author non-byline.;
• Is Part Of: European respiratory journal. Volume 51:Issue 5(2018)
• Publication Date: 2018-05-10
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02523-2017
• Languages: English
• ISSNs: 0903-1936

Abstract

Omalizumab is a monoclonal anti-IgE antibody used to treat severe allergic asthma (SAA). The aim of the STELLAIR study was to determine the importance of pre-treatment blood eosinophil count as a predictive measure for response to omalizumab. This retrospective real-life study was conducted in France between December 2015 and September 2016 using medical records of SAA omalizumab-treated patients. Response to omalizumab was assessed by three criteria: physician evaluation, reduction of ≥40% in annual exacerbation rate and a combination of both. Response rate was calculated according to blood eosinophil count measured in the year prior to omalizumab initiation. 872 SAA omalizumab-treated patients were included by 78 physicians (723 adults (age ≥18 years) and 149 minors (age 6–17 years)). Blood eosinophil count was ≥300 cells·µL −1 in 52.1% of adults and 73.8% of minors. By physician evaluation, 67.2% of adults and 77.2% of minors were responders and 71.1% adults and 78.5% minors had a ≥40% reduction in the exacerbation rate. In adults, the response rate for combined criteria was 58.4% (95% CI 53.2–63.4%) for blood eosinophils ≥300 cells·µL −1 (n=377) and 58.1% (95% CI 52.7–63.4%) for blood eosinophils <300 cells·µL −1 (n=346). This study shows that a large proportion of patients with SAA have a blood eosinophil count ≥300 cells·µL −1, and suggests that omalizumab effectiveness is similar in "high" and "low" eosinophil subgroups. Omalizumab is a treatment option for severe allergic asthma irrespective of blood eosinophil count http://ow.ly/7tQh30iXNTW